Sepsis, defined as life-threatening organ dysfunction due to a dysregulated host response to infection, is recognised by the World Health Organization as a global health priority. Each year, 5000 of the 18 000 adults with sepsis treated in Australian intensive care units die, with survivors suffering long-term physical, cognitive and psychological dysfunction, which is poorly recognised and frequently untreated. There are currently no effective pharmacological treatments for sepsis, making early recognition, resuscitation and immediate treatment with appropriate antibiotics the key to reducing the burden of resulting disease. The majority of sepsis, around 70-80%, is community acquired making emergency departments and primary care key targets to improve recognition and early management. Case fatality rates for sepsis are decreasing in many countries with the reduction attributed to national or regional screening and quality improvement programmes focused on early identification and immediate treatment. The optimum approach to treating established sepsis has been informed by high-quality, multicentre investigator initiated randomised trials with much of the valuable data coming from National Health and Medical Research Council-funded trials run from Australia. While early recognition and improved management of the acute episode are important steps in reducing death and disability from sepsis, a substantial reduction in the burden of sepsis-related disease requires action across the entire healthcare system. In this narrative review, we provide a summary of current knowledge on epidemiology of sepsis and septic shock and recommendations on the optimum approach to the management of these conditions in adults.
Introduction
Sepsis, now defined as life-threatening organ dysfunction due to a dysregulated host response to infection, 1 was recently recognised by the World Health Organization as a global health priority. 2 Sepsis causes or contributes to up to half of all in-hospital deaths in the USA. 3 Globally, the population incidence of hospital-treated sepsis in adults is estimated as 270 per 100 000, with overall mortality estimated at 26%. Without counting sepsis in children or occurring outside hospital, this equates to 19.4 million cases and 5.3 million deaths globally each year. 4 The most recent population-based estimate of sepsis in Australia is 188 per 100 000 with hospital mortality at 17.1%. Case rates for Aboriginal and Torres Strait Islander Australians are fourfold higher. 4, 5 Survivors of acute sepsis episodes are at an increased risk of death in the year following hospital discharge, 6 and over half of all survivors report reduced healthrelated quality-of-life with physical and cognitive impairment impacting their ability to perform usual activities of daily living. 7, 8 In May 2017, the World Health Assembly adopted a resolution co-sponsored by Australia to improve the prevention, diagnosis and management of sepsis worldwide. The resolution urges all United Nations member states to adopt a national action plan for sepsis and to include the prevention, diagnosis and treatment of sepsis in national health system strengthening efforts.
In this narrative review, we provide a summary of current approaches to the management of sepsis and septic shock focusing on adults.
Risk factors and diagnosis
Sepsis results from the host response to infection, consequently the populations at highest risk are those at greatest risk of contracting severe infections, these include the very young and the very old, and those with underlying noncommunicable diseases, such as diabetes, cancer and people with disease or treatment-related immunosuppression. 9 The definitions of sepsis and septic shock were updated in January 2016 with the goal of identifying patients at higher risk of adverse outcomes, specifically those needing treatment in an intensive care unit (ICU) or with a high risk of death. 1, 10 Previously, a diagnosis of sepsis required the presence of infection accompanied by two or more systemic inflammatory response syndrome (SIRS) criteria, and when accompanied by organ dysfunction this was designated 'severe sepsis' (Box 1). 11 The updated definition no longer considers the presence of infection and SIRS to indicate sepsis, and instead the diagnosis of sepsis requires an infection plus organ dysfunction indicated by an acute change in Sequential Organ Failure Assessment (SOFA) 12 of two points or more (Supporting Information Table S1 ). Thus, the old 'severe sepsis' becomes 'sepsis' with the new definition providing specific criteria to identify qualifying organ dysfunction for the first time. The most severe form of sepsis is septic shock, a state of circulatory failure that occurs in a subset of patients with sepsis in whom circulatory, cellular and metabolic abnormalities are associated with an increased risk of death. 10 The diagnosis of septic shock requires the presence of sepsis and hypotension requiring vasopressor therapy to maintain mean arterial pressure (MAP) 65 mmHg or greater and a serum lactate of greater than 2 mmol/L despite adequate fluid resuscitation. In settings where lactate measurement is not available, other indices of tissue hypoperfusion, such as oliguria, altered mental status (Glasgow Coma Scale of 13 or less) and delayed capillary refill, may be used instead. 10 While hyperlactaemia is not a specific sign of sepsis and is not part of the definition of sepsis, it is a valuable marker of disease severity and remains an important component of many effective screening programmes and treatment algorithms. [13] [14] [15] Common sites of infection and common microorganisms are documented in Table 1 .
The importance of screening, early recognition and early treatment There are currently no licensed pharmacological treatments for sepsis, but early recognition and treatment, particularly early administration of effective antibiotics, are associated with decreased mortality. 16, 17 While there has never been, and likely never will be, a prospective MSSA, coagulase negative staphylococcus †Only one-third of patients with septic shock have positive blood cultures. ‡In patients admitted with septic shock from the medical wards or the emergency department, the sepsis is predominantly of pulmonary origin. §In patients, admitted with septic shock from the operating room, the sepsis is predominantly of abdominal origin. In immunocompromised patients, in addition to the above, opportunistic infections from fungi, pneumocystis must be considered. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus. 17 In the New York study, risk-adjusted inhospital mortality was 28% in patients in who antibiotic treatment was delayed 12 h compared with 23% in patients who received antibiotics within 1 h, representing a 22% increase in relative risk of death. Taken together, these studies suggest that the relative risk of death from sepsis or septic shock may increase by between 4 and 8% for each hour of delay in administering effective antibiotics.
The majority, approximately 80%, of hospital-treated sepsis arises in the community and presents to emergency departments, with the remaining 20% occurring in patients already hospitalised for another reason. 18 This makes routine screening targeting early recognition and treatment in emergency departments an attractive strategy to reduce the number of deaths and such programmes have proven effective in Australia and in other countries. 13, 17 The New South Wales 'Sepsis Kills' programme focused on recognition of risk factors, signs and symptoms of sepsis, resuscitation with rapid administration of fluids and antibiotics and referral to senior clinicians and teams. Using the slogan RECOGNISE, RESUSCITATE, REFER, the programme increased the proportion of patients receiving antibiotics within 1 h of triage from 29.3 to 52.2% and was associated with a decrease in mortality from 19.3 to 14.1%, there was also a significant reduction in the time patients spent in an ICU. 13 Similar programmes are now being implemented in Queensland and Victoria. 13, 19, 20 Achieving similar improvements for the 20% of patients who develop sepsis in hospital is challenging as it requires the education of the entire clinical workforce, an enormous and ongoing, but not impossible commitment. The feasibility and results of this approach have been documented at the Peter MacCallum Cancer Centre where a whole of hospital nurse-led sepsis pathway produced significant improvement in time to diagnosis and treatment of sepsis associated with reduced rates of ICU admission, reduced post-sepsis length of stay and reduced sepsisrelated mortality. 21 Improvements are more likely if sepsis education can be incorporated into systems designed to recognise and respond to deteriorating patients as mandated by the Australian Commission on Safety and Quality in Health Care's National Safety and Quality Health Service Standard. 22 This approach entails training members of rapid response teams to recognise sepsis and to treat it as a time critical medical emergency. Such recognition is widespread in some national healthcare systems, notably in the UK, but not yet across Australia.
Systematic screening is recommended by the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock, 15 and by the UK National Confidential Enquiry into Patient Outcome and Nutrition -Commence enteral feeding early (see Table 2 )
Glucose control -Maintain blood glucose < 10 mmol/L (see Table 2 )
Venous Thromboembolism Prophylaxis -unfractioned heparin or low-molecular-weight heparin (see Table 2 ) Table 2 Death. A variety of screening tools are used around the world, for example, the National Early Warning Score in the UK, 22 the Sepsis Kills pathway in NSW 13, 22 and tools based on the SIRS criteria and markers of organ dysfunction in other countries. The recent working group on sepsis definitions suggested a new screening tool, the quick SOFA score. 1 The quick SOFA assigns one point for each of hypotension (systolic blood pressure ≤ 100 mmHg), tachypnoea (respiratory rate of ≥22 per minute) and altered mental status (Glasgow Coma Scale score of 13 or less) and is suggested as a simple way to identify patients with suspected infection who are likely to have a prolonged stay in intensive care or to die in hospital. Regardless of the screening system used, improved outcomes will only result if sepsis is identified and treated with minimum delay. Figure 1 outlines initial screening and management priorities for patients with sepsis and septic shock.
Management of patients with established sepsis Haemodynamic management
Treatment and resuscitation of patients with sepsis and septic shock should commence immediately and immediate priorities are the identification and control of the source infection, and its treatment with appropriate antibiotics. Infections for which urgent source control is indicated include abscesses amenable to percutaneous or surgical drainage, ischaemic bowel, gastrointestinal perforation, some infections of the biliary or urinary systems, necrotising soft tissue infection and infected implanted devices.
Haemodynamic management of sepsis related hypotension should commence immediately. The 2018 update of the Surviving Sepsis Campaign guidelines introduced the 'Hour-1 Bundle' which recommends treatment with intravenous fluids, measurement of serum lactate concentration as a marker of illness severity, administration of vasopressors, obtaining blood cultures and administering broad-spectrum antibiotics, all within the first hour.
14 Ideally, such treatment will be carried out or supervised by senior or experienced clinicians recognising that even with optimal treatment septic shock carries a high risk of death.
Septic shock is now defined as sepsis accompanied by hypotension requiring vasopressor therapy to maintain a MAP of 65 mmHg or greater and a serum lactate of greater than 2 mmol/L despite adequate fluid resuscitation. Sepsis-induced hypotension results from different pathological processes that require different treatments. Hypovolaemia from intravascular volume loss due to increased vascular permeability requires fluid resuscitation, vasodilatation affecting both the venous capacitance vessels and the arterial resistance vessels is treated with vasopressor agents, and sepsis-related myocardial dysfunction may require specific inotropic agents. 23 Protocols and algorithms for the management of sepsis-related hypotension are the focus of ongoing research. A landmark trial published in 2001 suggested that 'Early Goal Directed Therapy' (EGDT), a protocol based around using central venous oxygen saturation as a resuscitation target during the first 6 h of treatment, would significantly reduce mortality. 24 Patients randomly assigned to EGDT received more intravenous fluid, blood transfusions and inotropes in the first 6 h of treatment than those assigned to 'usual care'. Mortality was 46.5% with usual care and 30.5% with EGDT. As the study was conducted in a single hospital in the USA and open label it was considered at high risk of bias, and subsequently the protocol was tested in three large multi-centre trials in the USA, the UK and in Australia and New Zealand, and all three reported no benefit from EGDT. [25] [26] [27] [28] Not all commentators agree with the Surviving Sepsis Campaign Guideline recommendation to commence intravenous fluid resuscitation of sepsis-induced hypoperfusion at a rate of 30 mL/kg over 3 h, 15 and currently the bundle is under review because of concerns that its uncritical application may be harmful. 29 In response to the EGDT trials, more restrictive approaches to fluid resuscitation are currently being evaluated in randomised controlled trials (RCT). 30 While it is not possible to make firm evidence-based recommendations on individualising fluid therapy, it is common sense and good practice to review repeatedly individual patients and prescribe fluid resuscitation based on repeated assessment of ongoing need. There is widespread agreement that fluid resuscitation should commence with a crystalloid solution, either normal saline or a buffered salt solution, such as Hartmann's solution or PlasmaLyte. For patients who fail to respond to crystalloid resuscitation albumin can be added, although the evidence of its benefit remains equivocal. 31, 32 Hydroxyethyl starch should not be used as it increases the risk of acute kidney injury and death. 33 A restrictive approach to blood transfusion is safe and transfusing when haemoglobin concentration falls below 70 or 90 g/L results in equivalent mortality and morbidity. 34 Initial MAP target for patients with septic shock who require treatment with vasopressors should be 65 mmHg. In a trial comparing target MAP of 65-70 mmHg and 80-85 mmHg mortality outcomes were the same while those assigned the higher target received more vasopressors and had a higher risk of atrial fibrillation. In the
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Internal Medicine Journal 49 (2019) 160-170study, randomisation was stratified by presence or absence of chronic arterial hypertension, and in their electronic supplement, the authors report a reduction in use of renal replacement therapy in patients with chronic arterial hypertension assigned to the high MAP group. This raises the possibility that individualising treatment by targeting a MAP of 80-85 mmHg in such patients may improve some outcomes though a recent systematic review of vasopressor blood pressure targets in critically ill adults with hypotension did not support a higher MAP target. [35] [36] [37] Patients requiring vasopressors or ongoing fluid resuscitation should be treated in an ICU and undergo invasive vascular monitoring. Noradrenaline is the most commonly used vasopressor in Australian critical care practice and RCT support its use. In patients with sepsis, noradrenaline with dobutamine produced equivalent outcomes to adrenaline used alone. Adrenaline use results in a transient treatment-related lactic acidosis which, although not harmful, interferes with assessment of response to resuscitation. Historically, dopamine was a popular inotrope and vasopressor, but its use is associated with a nonsignificant increase in mortality and significantly greater risk of cardiac arrhythmias. Owing to a recent noradrenaline shortage, some hospitals in the USA were forced to use other vasopressor agents, most commonly phenylephrine patients with septic shock admitted to these hospitals at the time of the noradrenaline shortage had higher in-hospital mortality, 38 providing further support for the use of noradrenaline as the first line agent.
Vasopressin can be added to norepinephrine if required to achieve the target MAP although in two RCT its use did not reduce mortality. 39, 40 Selepressin, a selective vasopressin 1a receptor agonist, 41 and synthetic human angiotensin II, 42 are both effective vasopressors but do not have proven advantages compared to noradrenaline. Adding levosimendan, a calcium-sensitising inotropic agent with other properties, to standard care did not reduce organ dysfunction or mortality but was associated with more adverse effects.
Corticosteroids
There is an established biological rationale for the administration of adjunctive corticosteroids in the management of patients with septic shock. Corticosteroids act through two mechanisms: immune modulation and cardiovascular modulation. Evidence from RCT in the late 1980s demonstrated that high-dose methylprednisolone (30 mg/kg), although effective in reversing shock, did not reduce mortality in sepsis and that treatment with high dose corticosteroids was associated with increased mortality from superinfection. 43, 44 Studies in the late 1990s consistently demonstrated that treatment with lower doses of corticosteroids, typically hydrocortisone in a dose of 200 mg per 24 h, results in more rapid reversal of shock. 45 Concomitant with these findings was the observation that patients with a reduced cortisol response to an exogenous corticotropin stimulation test with adrenocorticotrophic hormone (ACTH) ('nonresponders, also termed 'relative adrenal insufficiency') had a higher mortality in severe sepsis. Two RCT produced divergent results on the efficacy of corticosteroids in reducing mortality, although both lacked the statistical power to demonstrate a clinically significant reduction in mortality. 46, 47 Recently, two large-scale RCT have added substantial new data to inform opinion regarding the role of corticosteroids in the treatment of septic shock. 48, 49 The Australia-based ADRENAL trial investigated the role of a continuous infusion of 200 mg/day of hydrocortisone compared with placebo in critically ill patients with septic shock; it reported no difference between groups with respect to short or longer term mortality, but patients assigned to hydrocortisone had earlier shock reversal, liberation from mechanical ventilation, reduced frequency of blood transfusion and earlier discharge from intensive care. 48, 50 The APROCCHS trial (n = 1241) examined the effect of 200 mg per day of hydrocortisone given as four 50 mg doses, combined with oral fludrocortisone compared to placebo and reported improved mortality in the steroid group, coupled with earlier shock reversal and earlier liberation from mechanical ventilation. 49 Metaanalyses, including the results of these two trials, have concluded that low dose corticosteroids produce either no or a very small reduction in short term mortality, but use is associated with more rapid resolution of shock, and shorter ICU stay. 51, 52 Currently, the Surviving Sepsis Campaign guidelines recommend against the use of lowdose corticosteroids if fluid resuscitation and vasopressor therapy are adequate in restoring hemodynamic stability. If hemodynamic instability persists despite adequate fluid resuscitation and vasopressor therapy, intravenous hydrocortisone can be added at a dose of 200 mg per day. The results from these recent RCT are likely to reinforce the role of steroids in septic shock and change the recommendation in future clinical practice guidelines.
Adjunctive therapies

Anti-inflammatory and immune stimulation strategies
The original rationale for treating sepsis with corticosteroids was that sepsis was an uncontrolled inflammatory response to infection and the anti-inflammatory effects of corticosteroids would improve outcomes. This same rationale spawned a multitude of clinical trials targeting the pathways and mediators of sepsis, including endotoxin, toll-like receptors, tumour necrosis factor α, interleukins, prostaglandins and leukotrienes, platelet activating factor, proteases, nitric oxide and others. None of these trials has resulted in a licensed and effective pharmaceutical for the treatment of sepsis, probably in part because some of the agents tested are ineffective, but also probably because of flaws in patient selection and trial design. 53 In developed healthcare systems, relatively few patients die rapidly of fulminant sepsis that is unresponsive to efforts at resuscitation, most deaths result from multiple organ failure and occur days or weeks after the onset of sepsis. In addition, patients who survive sepsis are at increased risk of being readmitted to hospital and suffering further episodes of infection and sepsis. 6, 54, 55 These observations and basic science research suggest that immunosuppression contributes significantly to delayed sepsis mortality, 56 and agents that stimulate immunity, such as Interleukin-7 and checkpoint inhibitors, may be beneficial in reducing sepsis mortality and morbidity. 57, 58 Renal replacement therapy and cytokine removal Septic shock is the most common cause of acute kidney injury in the ICU accounting for approximately half of all acute kidney injuries and is associated with the highest mortality. 59 Renal replacement therapy may be indicated for the treatment of uraemia, fluid overload and the metabolic derangement, such as severe hyperkalemia, that accompanies acute kidney injury. Renal replacement therapy, given almost exclusively as continuous venovenous haemodiafiltration in Australian ICU, lowers temperature and often lowers vasopressor requirements. Early use of renal replacement therapy is theoretically attractive as it may limit organ injury and fluid overload and remove inflammatory mediators responsible for the clinical manifestations of sepsis. 59 To date, there are no compelling data that strategies to remove cytokines, or to use more intensive renal replacement therapy, [60] [61] [62] [63] improve outcomes for patients with septic shock. Other management recommendations for patients with sepsis and septic shock are closely aligned with the general management of critically ill patients and are documented in Table 2 . Table 2 General management of the critically ill patient with sepsis and septic shock
Mechanical ventilation
Target tidal volumes of 6 mL/kg ideal bodyweight. If sepsis-related acute respiratory distress syndrome (ARDS) target tidal volumes of 6 mL/kg ideal bodyweight and plateau airway pressure of 30 cm H 2 O. In intensive care units (ICU) experienced in the practice, ventilate patients with severe ARDS in the prone position for 16 h each day. Extracorporeal membrane oxygenation (ECMO) may reduce mortality in patients with very severe ARDS, such patients should be referred to an ECMO retrieval service.
Venous thromboembolism prophylaxis
Pharmacologic prophylaxis using unfractionated heparin or low-molecular-weight heparin is recommended in the absence of contraindications to the use of these agents. Non-pharmacological prophylaxis recommendations include; anti-embolism stockings and consideration of passive and early mobilisation, where appropriate. Nutrition Early initiation of enteral feeding using trophic/hypocaloric or full enteral feeding is recommended in patients who can tolerate enteral feeding. Early feeding should be commenced within 48 h and feeding goals met ideally within 72 h of admission to the ICU. If enteral feeding is not fully established within a week, parenteral supplementation should be considered. Glucose control Blood glucose should be managed using a protocolised approach with commencement after two consecutive levels are >10 mmol/L. The target of blood glucose level is 6-10 mmol/L. Measurement should be conducted every 1-2 h until values and insulin infusion rates stabilise, then every 4 h thereafter in patients receiving insulin infusions. Sedation and analgesia Continuous or intermittent sedation should be minimised in mechanically ventilated patients. Common approaches include implementation of nurse-directed protocols, administration of intermittent sedation, and daily sedation interruption. Short-acting sedatives including propofol and dexmedetomidine may result in improved outcomes. Other pain, agitation and delirium guidelines provide additional detail on implementation of sedation management for mechanically ventilated patients with sepsis and septic shock. Positioning and early mobilisation
Elevate bed head between 30 and 45 for mechanically ventilated patients. Regular pressure area care as per unit specific guidelines. Active and early mobilisation should commence as soon as the patient is stable enough to participate. While, to date, no studies have found improvements in short-and long-term mortality active early mobilisation may improve mobility status and muscle strength, with several larger multicentre trials underway. Agreement on treatment goals Sepsis is common in elderly patients and in patients with serious underlying medical conditions and unlimited interventions will not be appropriate for all patients. Limitations to treatment may include both withholding and withdrawing life sustaining treatments when these will no longer produce an outcome acceptable to the individual patient. Agreement on treatment goals should whenever possible be informed by the patient's pre-stated wishes either to family or close friends or in legal documents such as advance directives or living wills.
Sepsis and septic shock
Internal Medicine Journal 49 (2019) 160-170 Multicentre retrospective cohort study
Introduction of the Sepsis Kills programme was associated with significant increase in proportion of patients receiving antibiotics and commencing 2nd litre of intravenous within first hour of diagnosis of sepsis. These practice changes were associated with significant reduction in mortality. Comprehensive evidence review focused mainly on initial resuscitation and care in the ICU †Rhodes 2016 provides comprehensive evidence-based guidelines (Surviving Sepsis Campaign Guidelines) for managing patients with sepsis and septic shock. While this is not a major investigated initiated trial, it is included as it is a valuable resource for clinicians and researchers. ICU, intensive care unit; RCT, randomised controlled trial.
Thompson et al.
Internal Medicine Journal 49 (2019) 160-170 Table 3 provides a list of important research that has informed the current clinical management of sepsis and septic shock.
General intensive care management
Patients with respiratory failure requiring positive pressure mechanical ventilation should have target tidal volumes of 6 mL/kg ideal bodyweight. For adult patients with sepsis-related acute respiratory distress syndrome (ARDS), a ventilation strategy targeting a tidal volumes of 6 mL/kg ideal bodyweight and a plateau airway pressure of 30 cm H 2 O results in lower mortality than allowing larger tidal volumes and a higher plateau pressure. 64 A restrictive approach to fluid administration is also beneficial. 65 In ICU experienced in the practice, ventilating patients with severe ARDS in the prone position for 16 h each day significantly reduced mortality. 66 A recent trial lends further support to the contention that extracorporeal membrane oxygenation (ECMO) reduces mortality in patients with very severe ARDS, 67 such patients should be referred to specialist ECMO centres who offer an ECMO retrieval service as safe transport requires ECMO to be established at the referring hospital.
Personalised medicine
Clinicians treating patients with sepsis recognise marked inter-patient variability in response to treatment, and it is clear that genetic factors play an important role in susceptibility to sepsis and response to treatment. A landmark study of Danish adoption records reported that adopted children whose biological parent had died before the age of 50 from an infective cause had a fivefold increase in the relative risk of death from infection. There was no corresponding increase in risk of death from sepsis if it was the adoptive parent who died from the same cause. 68 Since then, many studies have sought to understand the genetic basis of sepsis. 69 The development of sepsis-specific biomarkers and molecular diagnostics for the assessment of the host response and for pathogen detection is the subject of ongoing research and success would likely result in improved patient outcomes. Around 180 distinct molecules have been proposed as potential biomarkers of sepsis, given its biological complexity a panel of multiple biomarkers may be the best risk stratification tool. 70, 71 Pharmacogenomics is a rapidly evolving field in the area of sepsis with the ultimate goal of identifying which patients are likely to benefit from or be harmed by particular drug treatments; as yet this research has produced no tangible clinical benefits for the management of sepsis.
Longer term morbidity and increased healthcare resource use of sepsis survivors Although mortality from sepsis and septic shock remains unacceptably high, it is decreasing around the world making the long-term effects suffered by the increasing number of survivors sufficiently important to be labelled a hidden public health disaster. Compared with matched controls survivors suffer physical, psychological and cognitive impairments, use more healthcare resources and are more likely to die in the years following sepsis. 6, 7, 54 Risk factors for post-sepsis morbidity likely include poorer pre-existing health status, the severity and duration of the acute sepsis episode and treatment-related factors, including timeliness and treatment-related harm. 72 Strategies to minimise the long term effects of sepsis may not differ from those needed for other survivors of serious critical illness. 73 Current accepted strategies during ICU treatment include early mobilisation. 74 and minimising sedation. 75 The optimum management strategies after ICU and hospital discharge remain to be elucidated but likely involve increasing awareness among the many specialists and general practitioners to whom patients with post-sepsis morbidity may present.
Conclusion
While acute case fatality rates of sepsis are decreasing, the ageing population and increasing incidence, together with greater appreciation that sepsis is followed by longer term physical, psychologic and cognitive impairment, means that sepsis poses an increasing public health problem. While early recognition and improved management of the acute episode will pay dividends, a substantial reduction in the burden of sepsis-related disease requires action across the healthcare system. Optimum strategies to manage the acute episode are well developed and based on evidence from high quality and large scale multi-centre clinical trials. Strategies to prevent and treat sepsis sequelae are less well developed and should be a priority for future research.
